Abobotulinum toxin A
ApprovedSmall molecule
Abobotulinum toxin A is one of 17 small molecule programs targeting Tremor. It is currently in Approved.
1
Indications
4
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
21 competitors in Tremor
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Topamax
WWim Janssens
Phase 3
Neurontin
VViatris Specialty LLC
Phase 3
Xyrem
Jazz PharmaceuticalsPhase 2
Epidiolex
Jazz PharmaceuticalsPhase 2
XEOMIN
MMerz Pharmaceuticals GmbH
Phase 2
Onabotulinumtoxin a
LundbeckPhase 2
Alcohol
AstellasPhase 2
Abobotulinum toxin A
FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Approved
Bont-a
SSir Run Run Shaw Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tourette's Syndrome1 trial
Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome
Unknown status·—·N/A·NCT02187679·30 enrolled
Mobility1 trial
Tremor1 trial
A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor
Recruiting·—·Phase 4·NCT03136341·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Abobotulinum toxin A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details